Page 267 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

246 PART III Therapeutic Modalities for the Cancer Patient

121. van der Meijden AP: Non-specific immunotherapy with bacille 141. Anderson PM, Tomaras M, McConnell K: Mifamurtide in osteo-
Calmette-Guerin (BCG), Clin Exp Immunol 123(2):179–180, sarcoma—a practical review, Drugs Today (Barc) 46(5):327–337,
2001. 2010.
VetBooks.ir 122. Vita F, Siracusano S, Abbate R, et al.: BCG prophylaxis in blad- 142. Kurzman ID, MacEwen EG, Rosenthal RC, et al.: Adjuvant ther-
apy for osteosarcoma in dogs: results of randomized clinical trials
der cancer produces activation of recruited neutrophils, Can J Urol
18(1):5517–5523, 2011.
123. Ludwig AT, Moore JM, Luo Y, et al.: Tumor necrosis factor- using combined liposome-encapsulated muramyl tripeptide and
cisplatin, Clin Cancer Res 1(12):1595–1601, 1995.
related apoptosis-inducing ligand: a novel mechanism for Bacil- 143. Fox LE, King RR, Shi F, et al.: Induction of serum tumor necrosis
lus Calmette-Guerin-induced antitumor activity, Cancer Res factor-alpha and interleukin-6 activity by liposome-encapsulated
64(10):3386–3390, 2004. muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) in
124. Herr HW, Morales A: History of bacillus Calmette-Guerin and normal cats, Cancer Biother 9(4):329–340, 1994.
bladder cancer: an immunotherapy success story, J Urol 179(1):53– 144. Vail DM, MacEwen EG, Kurzman ID, et al.: Liposome-encap-
56, 2008. sulated muramyl tripeptide phosphatidylethanolamine adju-
125. Klein WR, Rutten VP, Steerenberg PA, Ruitenberg EJ: The present vant immunotherapy for splenic hemangiosarcoma in the dog:
status of BCG treatment in the veterinary practice, Vivo 5(6):605– a randomized multi-institutional clinical trial, Clin Cancer Res
608, 1991. 1(10):1165–1170, 1995.
126. Debruyne FM, van der Meijden AP, Schreinemachers LM, et al.: 145. MacEwen EG, Kurzman ID, Vail DM, et al.: Adjuvant therapy
Intravesical and intradermal BCG-RIVM application: a toxicity for melanoma in dogs: results of randomized clinical trials using
study, Prog Clin Biol Res 185B:151–159, 1985. surgery, liposome-encapsulated muramyl tripeptide, and granu-
127. Knapp DW, Glickman NW, Denicola DB, Bonney PL, Lin TL, locyte macrophage colony-stimulating factor, Clin Cancer Res
Glickman LT: Naturally-occurring canine transitional cell carci- 5(12):4249–4258, 1999.
noma of the urinary bladder: a relevant model of human invasive 146. Teske E, Rutteman GR, vd Ingh TS, et al.: Liposome-encapsu-
bladder cancer, Urol Oncol 5(2):47–59, 2000. lated muramyl tripeptide phosphatidylethanolamine (L-MTP-
128. Mukaratirwa S, Chitanga S, Chimatira T, et al.: Combination PE): a randomized clinical trial in dogs with mammary
therapy using intratumoral bacillus Calmette-Guerin (BCG) and carcinoma, Anticancer Res 18(2A):1015–1019, 1998.
vincristine in dogs with transmissible venereal tumours: therapeu- 147. MacEwen EG, Kurzman ID, Rosenthal RC, et al.: Therapy for
tic efficacy and histological changes, J S Afr Vet Assoc 80(2):92–96, osteosarcoma in dogs with intravenous injection of liposome-
2009. encapsulated muramyl tripeptide, J Natl Cancer Inst 81(12):935–
129. Henry CJ, Downing S, Rosenthal RC, et al.: Evaluation of a novel 938, 1989.
immunomodulator composed of human chorionic gonadotropin and 148. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Pot-
bacillus Calmette-Guerin for treatment of canine mast cell tumors in ter TA: Lipid-DNA complexes induce potent activation of innate
clinically affected dogs, Am J Vet Res 68(11):1246–1251, 2007. immune responses and antitumor activity when administered intra-
130. Lipton A, Harvey HA, Balch CM, et al.: Corynebacterium parvum venously, J Immunol 163(3):1552–1561, 1999.
versus bacille Calmette-Guerin adjuvant immunotherapy of stage 149. Zaks K, Jordan M, Guth A, et al.: Efficient immunization and
II malignant melanoma, J Clin Oncol 9(7):1151–1156, 1991. cross-priming by vaccine adjuvants containing TLR3 or TLR9 ago-
131. MacEwen EG, Patnaik AK, Harvey HJ, et al.: Canine oral mela- nists complexed to cationic liposomes, J Immunol 176(12), 2006.
noma: comparison of surgery versus surgery plus Corynebacterium 7335–4735.
parvum, Cancer Invest 4(5):397–402, 1986. 150. Hemmi H, Takeuchi O, Kawai T, et al.: A Toll-like receptor recog-
132. Misdorp W: Incomplete surgery, local immunostimulation, and nizes bacterial DNA, Nature 408(6813):740–745, 2000.
recurrence of some tumour types in dogs and cats, Vet Q 9(3):279– 151. Sellins K, Fradkin L, Liggitt D, Dow S: Type I interferons potently
286, 1987. suppress gene expression following gene delivery using liposome(-)
133. Luo X, Li Z, Lin S, et al.: Antitumor effect of VNP20009, an DNA complexes, Mol Ther 12(3):451–459, 2005.
attenuated Salmonella, in murine tumor models, Oncol Res 12(11- 152. Dow S, Elmslie R, Kurzman I, et al.: Phase I study of liposome-
12):501–508, 2001. DNA complexes encoding the interleukin-2 gene in dogs with
134. Leschner S, Westphal K, Dietrich N, et al.: Tumor invasion of osteosarcoma lung metastases, Hum Gene Ther 16(8):937–946,
Salmonella enterica serovar typhimurium is accompanied by strong 2005.
hemorrhage promoted by TNF-alpha, PLoS One 4(8):e6692, 2009. 153. Kamstock D, Guth A, Elmslie R, et al.: Liposome-DNA complexes
135. Saccheri F, Pozzi C, Avogadri F, et al.: Bacteria-induced gap junc- infused intravenously inhibit tumor angiogenesis and elicit anti-
tions in tumors favor antigen cross-presentation and antitumor tumor activity in dogs with soft tissue sarcoma, Cancer Gene Ther
immunity, Sci Transl Med 2(44):44ra57, 2010. 13(3):306–317, 2006.
136. Toso JF, Gill VJ, Hwu P, et al.: Phase I study of the intravenous 154. MacNeill AL: On the potential of oncolytic virotherapy for the
administration of attenuated Salmonella typhimurium to patients treatment of canine cancers, Oncolytic Virother 4:95–107, 2015.
with metastatic melanoma, J Clin Oncol 20(1):142–152, 2002. 155. Smith BF, Curiel DT, Ternovoi VV, et al.: Administration of a
137. Thamm DH, Kurzman ID, King I, et al.: Systemic administration conditionally replicative oncolytic canine adenovirus in normal
of an attenuated, tumor-targeting Salmonella typhimurium to dogs dogs, Cancer Biother Radiopharm 21(6):601–606, 2006.
with spontaneous neoplasia: phase I evaluation, Clin Cancer Res 156. Le LP, Rivera AA, Glasgow JN, et al.: Infectivity enhancement for
11(13):4827–4834, 2005. adenoviral transduction of canine osteosarcoma cells, Gene Ther
138. Kleinerman ES, Jia SF, Griffin J, et al.: Phase II study of lipo- 13(5):389–399, 2006.
somal muramyl tripeptide in osteosarcoma: the cytokine cascade 157. Hemminki A, Kanerva A, Kremer EJ, et al.: A canine condition-
and monocyte activation following administration, J Clin Oncol ally replicating adenovirus for evaluating oncolytic virotherapy in a
10(8):1310–1316, 1992. syngeneic animal model, Mol Ther 7(2):163–173, 2003.
139. Asano T, Kleinerman ES: Liposome-encapsulated MTP-PE: a 158. Suter SE, Chein MB, von Messling V, et al.: In vitro canine
novel biologic agent for cancer therapy, J Immunother Emphasis distemper virus infection of canine lymphoid cells: a prelude to
Tumor Immunol 14(4):286–292, 1993. oncolytic therapy for lymphoma, Clin Cancer Res 11(4):1579–
140. Gianan MA, Kleinerman ES: Liposomal muramyl tripeptide (CGP 1587, 2005.
19835A lipid) therapy for resectable melanoma in patients who 159. Gentschev I, Ehrig K, Donat U, et al.: Significant growth inhibi-
were at high risk for relapse: an update, Cancer Biother Radiopharm tion of canine mammary carcinoma xenografts following treatment
13(5):363–368, 1998. with oncolytic vaccinia virus GLV-1h68, J Oncol 736907, 2010.